FEEDBACK ON PHARMAC PROPOSAL - FUNDING OF VILDAGLIPTIN

Diabetes NZ submission to Pharmac in response to their consultation document affecting the funding of Diabetes medication.

Please find below feedback from Diabetes New Zealand, about Pharmac’s proposal relating to the future funding of Vildagliptin a DPP4 inhibitor.

It is excellent that Pharmac propose funding Vildagliptin, a new class of medication for diabetes. However, there are other classes of medication that have more proven health benefits than Vildagliptin. We feel that our population of people with diabetes should be funded for a variety of the new classes of medication that offers them best health outcomes according to international evidence and guidelines.